All In Biotech

Free tool

FAERS Monitor: Hetlioz Lq

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214517 or its brand name (Hetlioz Lq, Tasimelteon). Reports on generic versions are filed under their own applications.

Reports

5,893

Serious

601

10% of reports

Hospitalization

288

Death reported

166

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective1,652
  • insomnia747
  • product dose omission issue504
  • middle insomnia424
  • somnolence412
  • headache387
  • nightmare272
  • fatigue225
  • abnormal dreams224
  • therapeutic product effect decreased199
  • sleep disorder193
  • inappropriate schedule of product administration185
  • incorrect product administration duration165
  • poor quality sleep159
  • initial insomnia153

Reports by year received

View as table
YearReports
20149
2015577
2016408
2017308
2018540
2019776
2020741
2021731
2022556
2023562
2024377
2025177
2026131

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,266 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
middle insomniaSignal42482.975.633,482
initial insomniaSignal15354.046.17,793
abnormal dreamsSignal22429.225.76,027
nightmareSignal27228.325.27,084
incorrect product administration durationSignal16527.423.54,141
poor quality sleepSignal15926.522.83,859
therapeutic product effect decreasedSignal19915.913.92,762
insomniaSignal74710.09.46,128
sleep disorderSignal1939.88.51,514
somnolenceSignal4127.36.72,257
product dose omission issueSignal5046.15.62,183
drug ineffectiveSignal1,6524.54.34,752
inappropriate schedule of product administrationSignal1853.73.2359
headacheSignal3872.22.0261
fatigue2251.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.